Nearly all treatments, including drugs and medical devices, require clinical trials and approval by the government’s Food and Drug Administration (FDA). The journey from a scientific breakthrough to a treatment you can access is a long one -- taking years. (The recent approvals of COVID-19 vaccines are welcome exceptions to that timeframe.) A clinical trial is a research study using
January is Glaucoma Awareness Month Be Well-Informed Here’s a New Year’s resolution that can save your sight: make that call to schedule an appointment to have your eyes tested. The pandemic forced many offices to close in early spring but many reopened in the summer, although often seeing fewer patients than before the pandemic. While COVID 19 is still rampant
January is Glaucoma Awareness Month Glaucoma is a leading cause of vision loss and blindness in the United States. Right now, there are as many as 40 million people around the world who aren’t yet aware that glaucoma is silently stealing their sight. Glaucoma can sneak up on you. And though there isn’t yet a cure, early detection and treatment
Doctor, I Have A Question: What's New in Genetics Research? Our Scientific Advisory Board Member Dr. John H. Fingert, MD, PhD shares some of the new developments in glaucoma and genetics research. Click the image below to enlarge the article.
The Glaucoma Foundation (TGF) and Columbia University Medical Center (CUMC) Announce Inaugural Cohort of Hill-Eisenberg Glaucoma Fellows The Patricia Hill-Dr. Sanford Eisenberg Fellowship in Glaucoma was founded this spring by Ms. Patricia Hill, a member of the board of directors of The Glaucoma Foundation. These annual grants will support women and minorities in the study of glaucoma. Click the
TGF is conducting a survey to learn about your experiences with various glaucoma treatments. The Glaucoma Foundation is partnering with a major pharmaceutical company to give you the opportunity to share some of your experiences with glaucoma medications and delivery systems. Understanding your needs and concerns will drive advancements in treatment, making it easier and safer to manage glaucoma with
Our latest Eye to Eye Newsletter is here! These newsletters are mailed out four times a year. If you would like to receive it please click here to send us your mailing address.
Did you miss our live panel? Click here to watch the video. Award-winning documentary filmmaker Joseph Lovett has glaucoma, a disease that affects an estimated 80 million people around the world and robs 4.5 million of their vision. After years of slowly losing his sight, Joe's fear of going blind intensifies; he needs to understand how other people are living
During these days when so many of us are spending increased hours working or communicating in front of a home computer or another digital screen, it’s particularly important for those living with glaucoma to be aware of concerns regarding excessive digital use. Dry eyes, watery eyes, blurred vision, and increased sensitivity to light are some of the most common symptoms
Award-winning documentary filmmaker Joseph Lovett has glaucoma, a disease that affects an estimated 80 million people around the world and robs 4.5 million of their vision. After years of slowly losing his sight, Joe's fear of going blind intensifies; he needs to understand how other people are living with their vision loss. Joe's pursuit leads him to places and people